Literature DB >> 18296494

Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats.

Hong Ji1, Stefano Menini, Wei Zheng, Carlo Pesce, Xie Wu, Kathryn Sandberg.   

Abstract

17beta-Oestradiol (E2)-mediated inhibition of angiotensin-converting enzyme (ACE) protects the E2-replete kidney from the progression of hypertensive renal disease. Angiotensin-converting enzyme 2 (ACE2), a homologue of ACE, counters the actions of ACE by catalysing the conversion of angiotensin II (Ang II) to angiotensin(1-7) [Ang(1-7)]. We investigated E2 regulation of ACE2 in the renal wrap (RW) model of hypertension in rats. After 6 weeks on a high-sodium diet (4% NaCl), the activity of ACE2 was reduced in the renal cortex by 31%, which was mirrored by similar decreases in ACE2 protein (30%) and mRNA expression (36%) in the ovariectomized RW rat (RW-OVX); E2 replacement prevented these effects. The RW-OVX rats exhibited greater renal injury, including 1.7-fold more tubulointerstitial fibrosis and 1.6-fold more glomerulosclerosis than E2-replete females (RW-Intact and RW-OVX+E2). Angiotensin(1-7) infusion prevented these exacerbating effects of ovariectomy on renal pathology; no differences in indicators of renal injury were observed between RW-OVX-Ang(1-7) and RW-Intact rats. These renal protective effects of Ang(1-7) infusion were not attributable to increased ACE2 activity or to changes in heart rate or body weight, since these parameters were unchanged by Ang(1-7) infusion. Furthermore, Ang(1-7) infusion did not attenuate renal injury by reducing mean arterial pressure (MAP), since infusion of the peptide did not lower MAP but rather caused a slight increase during a 6 week chronic treatment for Ang(1-7). These results suggest that E2-mediated upregulation of renal ACE2 and the consequent increased Ang(1-7) production contribute to E2-mediated protection from hypertensive renal disease. These findings have implications for E2-deficient women with hypertensive renal disease and suggest that therapeutics targeted towards increasing ACE2 activity and Ang(1-7) levels will be renal protective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18296494     DOI: 10.1113/expphysiol.2007.041392

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  50 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Authors:  Minghao Ye; Jan Wysocki; Francisco R Gonzalez-Pacheco; Mahmoud Salem; Karla Evora; Laura Garcia-Halpin; Marko Poglitsch; Manfred Schuster; Daniel Batlle
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

3.  Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension.

Authors:  Baojian Xue; Zhongming Zhang; Terry G Beltz; Fang Guo; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

4.  Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men.

Authors:  A Bukowska; L Spiller; C Wolke; U Lendeckel; S Weinert; J Hoffmann; P Bornfleth; I Kutschka; A Gardemann; B Isermann; A Goette
Journal:  Exp Biol Med (Maywood)       Date:  2017-06-29

5.  Molecular and Cellular Effect of Angiotensin 1-7 on Hypertensive Kidney Disease.

Authors:  Yuanjian Chen; Wenyuan Zhao; Chang Liu; Weixin Meng; Tieqiang Zhao; Syamal K Bhattacharya; Yao Sun
Journal:  Am J Hypertens       Date:  2019-04-22       Impact factor: 2.689

Review 6.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 7.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease.

Authors:  Austin C Boese; Seong C Kim; Ke-Jie Yin; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

8.  Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.

Authors:  Thomas Simon O'Hagan; Whitney Wharton; Patrick Gavin Kehoe
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Androgen Receptor Blockade Differentially Regulates Blood Pressure in Growth-Restricted Versus Ovarian Deficient Rats.

Authors:  Gwendolyn K Davis; Suttira Intapad; Ashley D Newsome; Laura E Coats; Daniel R Bamrick; Norma B Ojeda; Barbara T Alexander
Journal:  Hypertension       Date:  2019-08-05       Impact factor: 10.190

Review 10.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.